Endo Pharmaceuticals News

's stock had its "neutral" rating reaffirmed by research analysts at Goldman Sachs in a report released on Wednesday.

Endo Health Solutions Inc. to Present at the Goldman, Sachs & Co. 33rd Annual Global Healthcare Conference , executive vice president and chief financial officer, will present a corporate overview at the Goldman Sachs 33rd Annual Global Healthcare Conference on A live webcast and audio archive of the presentation will be available on the company's ... (more)

Endo Health Solutions Inc. to Present at Jefferies and Co. 2012 Global Healthcare Conference A live webcast and audio archive of the presentation will be available on the company's website at http://www.endo.com/ . Click on Investor Relations, and then the link to the Event and Presentation.

In trading on Friday, shares of Endo Health Solutions Inc crossed above their 200 day moving average of $33.67, changing hands as high as $33.69 per share.

CHADDS FORD, Pa., May 23, 2012 /PRNewswire-FirstCall/ -- Shareholders of Endo Pharmaceuticals Holdings Inc.

RALEIGH, N.C., May 10, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc.

The group received 90 percent of its $5 million in funding in 2010 from the drug and medical-device industry, ProPublica found, and its guides for patients, journalists and policymakers had played down the risks associated with opioid painkillers while exaggerating the benefits.

A U.S. Senate panel has launched a probe of possible links between three drugmakers and nonprofit medical groups that advocated for increasing the use of prescription painkillers, now the target of a nationwide law enforcement crackdown.

's stock had its "neutral" rating reaffirmed by Zacks in a report released on Friday.

CHADDS FORD, Pa., May 4, 2012 /PRNewswire/ -- Endo today announced that Alan Levin, executive vice president and chief financial officer, will present a corporate overview at the Bank of America Merrill Lynch 2012 Heath Care Conference on Wednesday, May 16, 2012 at 12:20 p.m. ET.

Several other analysts have also recently commented on the stock. Analysts at Citigroup set a $48.00 price target on shares of Endo Pharmaceuticals in a research note to investors on Monday, March 26th.